Recent Research: Tetanus Vaccine Market Forecast From 2018 To 2023
Qurate Research announces the addition of new study based research report on “Tetanus Vaccine Market” to their suite of offerings.
(EMAILWIRE.COM, October 13, 2018 ) This report covers the present scenario (with the base year being 2017) and the growth prospects of Global Tetanus Vaccine Market Report for 2018-2023.
Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth given during adolescence. Additional doses every 10 years are recommended. After three doses almost everyone is initially immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury. In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-58929
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.Over the next five years, Expert projects that Tetanus Vaccine will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
For Enquiry, Visit@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-58929
To calculate the market size, Expert considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Segmentation by application:
Adult
Pediatric
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Direct Purchase@ https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-58929/
Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth given during adolescence. Additional doses every 10 years are recommended. After three doses almost everyone is initially immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury. In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-58929
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.Over the next five years, Expert projects that Tetanus Vaccine will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
For Enquiry, Visit@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-58929
To calculate the market size, Expert considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Segmentation by application:
Adult
Pediatric
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Direct Purchase@ https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-58929/
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results